Please login to the form below

Not currently logged in
Email:
Password:

Astellas picks Dr Charlotte Kremer to lead new medical affairs organisation

She joins the pharma company from Pfizer to take up a new global role

Astellas Dr Charlotte KremerDr Charlotte Kremer has moved from Pfizer to Astellas to lead the Japanese pharma company's new global medical affairs organisation.

Based at Astellas' Illinois headquarters for its Americas operations, Dr Kremer will be tasked with providing “global leadership for medical excellence and a unified medical perspective”.

The company's Global Medical Affairs unit is one of its newest organisations and, although based in the US, may work with a variety of supporting positions from across the regions in which Astellas is active.

"We are thrilled to have Charlotte join Astellas. She brings years of experience and an outstanding reputation to this new, global leadership role," said Yoshihiko Hatanaka, president and CEO of Astellas Pharma Inc., the parent company of Astellas US LLC.

"Further globalising our key functions, such as medical affairs, is a top priority at Astellas because of the value it brings to the company in this competitive global business environment."

Dr Kremer has spent 20 years in the pharmaceutical industry, most recently serving at Pfizer as VP and therapeutic area head for ophthalmology, PVD, rare diseases and neuroscience.

Prior to joining Pfizer she worked at Organon in the Netherlands and the US, providing medical support, developing phase IIIb/IV clinical trials and initiated and developed a medical liaison programme.

23rd February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...